With this agreement, PharmaNet will have to access potential subjects who are suffering from mild, moderate, or severe impaired renal function.
PharmaNet Early Stage Development president Riaz Bandali said demand for the conduct of pharmacokinetic studies in patients with impaired renal function is increasing.
"By partnering with HMR, we can efficiently conduct trials in patients with various levels of renal impairment, while assuring the patients’ safety and well-being," Bandali said.